OPN-375
Sponsors
Optinose US Inc.
Conditions
Bilateral Nasal PolyposisChronic RhinosinusitisChronic Rhinosinusitis Without Nasal Polyps
Phase 3
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
CompletedNCT03747458
Start: 2018-12-31End: 2026-06-11Updated: 2026-09-18
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
CompletedNCT03781804
Start: 2018-11-27End: 2022-01-19Updated: 2024-05-29
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
CompletedNCT03960580
Start: 2019-06-06End: 2022-05-04Updated: 2023-12-21
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
RecruitingNCT06850805
Start: 2025-07-28End: 2028-10-31Target: 84Updated: 2026-09-18